Sotera Health Revenue Growth Rates (SHC), Current and Historic Growth - CSIMarket
CSIMarket
 


Sotera Health Company  (NASDAQ: SHC)
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 

SHC's Revenue Growth by Quarter and Year

Sotera Health's Revenue results by quarter and year




SHC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 321.38
1st Quarter March 279.07
FY 600.44

SHCs Annual Revenue
Sotera Health's Revenue in the fiscal year 2025 $ 1,163.53 millions
Sotera Health's Revenue in the fiscal year 2024 $ 1,100.30 millions
Sotera Health's Revenue in the fiscal year 2023 $ 1,049.16 millions
Sotera Health's Revenue in the fiscal year 2022 $ 1,003.69 millions
Sotera Health's Revenue in the fiscal year 2021 $ 931.48 millions




SHC Revenue second quarter 2026 Y/Y Growth Comment
Sotera Health Company achieved in the second quarter 2026, above Company average Revenue improvement of 9.45% year on year, to $ 321.38 millions.

Looking into second quarter 2026 results within Healthcare Facilities industry 11 other companies have achieved higher Revenue growth. While Sotera Health Company' s Revenue increase of 9.45% ranks overall at the positon no. 1778 in the second quarter 2026.




SHC Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter December - 4.65 % -6.31 % 23.61 %
3rd Quarter September - 8.96 % 8.38 % 5.74 %
2nd Quarter June 9.45 % 6.47 % 8.33 % -4.52 %
1st Quarter March 9.68 % 2.54 % 12.48 % -6.83 %
FY   - 5.75 % 4.87 % -

Financial Statements
Sotera Health's second quarter 2026 Revenue $ 321.38 millions SHC's Income Statement
Sotera Health's second quarter 2025 Revenue $ 293.62 millions Quarterly SHC's Income Statement


SHC Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter December - -1.82 % 2.23 % 18.26 %
3rd Quarter September - 5.77 % 3.35 % 3.3 %
2nd Quarter June 15.16 % 15.4 % 11.15 % 15.41 %
1st Quarter March -8.48 % -12.68 % -20.22 % -12.32 %
FY (Year on Year)   - 5.75 % 4.87 % -




Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #12
Healthcare Sector #280
Overall #1778

Revenue Y/Y Growth Statistics
High Average Low
23.61 % 7.71 % -6.83 %
(Sep 30 2024)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #12
Healthcare Sector #280
Overall #1778
Revenue Y/Y Growth Statistics
High Average Low
23.61 % 7.71 % -6.83 %
(Sep 30 2024)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sotera Health's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18.75 % 2.73 % -20.22 %
(Jun 30 2021)  


SHC's II. Quarter Q/Q Revenue Comment
Sotera Health Company achieved in the II. Quarter 2026 above company average sequential Revenue jump of 15.16%, to $ 321.38 millions, from $279.07 millions in the first quarter.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Sotera Health's Revenue growth quarter on quarter, overall rank is 622.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #112
Overall #622
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #112
Overall #622
Revenue Q/Q Growth Statistics
High Average Low
18.75 % 2.73 % -20.22 %
(Jun 30 2021)  


SHC's II. Quarter Q/Q Revenue Comment
Sotera Health Company achieved in the II. Quarter 2026 above company average sequential Revenue jump of 15.16%, to $ 321.38 millions, from $279.07 millions in the first quarter.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Sotera Health's Revenue growth quarter on quarter, overall rank is 622.


Sotera Health's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending
(Mar 31 2026)
12 Months Ending
(Dec 31 2025)
12 Months Ending
(Sep 30 2025)
12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,215.93 $ 1,188.17 $ 1,163.53 $ 1,149.98 $ 1,124.44
Y / Y Revenue Growth (TTM) 8.14 % 7.37 % 5.75 % 2.68 % 2.42 %
Year on Year Revenue Growth Overall Ranking # 2371 # 827 # 1092 # 684 # 817
Seqeuential Revenue Change (TTM) 2.34 % 2.12 % 1.18 % 2.27 % 1.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 2469 # 2405 # 1538 # 1485 # 1891


Cumulative Revenue growth Comment
Sotera Health saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 8.14% year on year, to $ 1,216 millions if the fiscal year would have ended in Jun 30 2026.
Sotera Health's trailing twelve months Revenue growth was higher than company's average 6.92% and higher than 7.37% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 2.34 % from $1188.17 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.92%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.34 % increase from $1188.17 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 342 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2371.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 26
Healthcare Sector # 343
Overall # 2371

Revenue TTM Y/Y Growth Statistics
High Average Low
13.85 %
6.92 %
-0.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 356
S&P 500 # 2469
Cumulative Revenue growth Comment
Sotera Health saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 8.14% year on year, to $ 1,216 millions if the fiscal year would have ended in Jun 30 2026.
Sotera Health's trailing twelve months Revenue growth was higher than company's average 6.92% and higher than 7.37% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 2.34 % from $1188.17 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.92%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.34 % increase from $1188.17 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 342 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2371.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 26
Healthcare Sector # 343
Overall # 2371

Revenue TTM Y/Y Growth Statistics
High Average Low
13.85 %
6.92 %
-0.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 356
S&P 500 # 2469




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SHC's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions


About Sotera Health Revenue Growth Rates (SHC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sotera Health Co (CIK 1822479).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001822479-26-000047
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sotera Health Co’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.